Denali Therapeutics (DNLI) is back in focus after accelerated FDA approval of AVLAYAH, its first commercial product for neurologic Hunter syndrome in pediatric patients, with U.S. launch underway and initial payer discussions progressing.

The AVLAYAH approval and pipeline updates come after a mixed share price pattern, with the stock up 20.59% year to date but longer term total shareholder returns still materially below earlier levels. This suggests sentiment is rebuilding rather than fully recovered.

If AVLAYAH has put rare disease and neurology stocks on your radar, this could be a useful moment to scan for other healthcare-focused AI opportunities through our 34 healthcare AI stocks

So with Denali stock still well below its multi year highs, yet up strongly over the past year and analysts’ targets sitting above the current price, should you see upside from here or assume the market is already pricing in future growth?

Preferred Price to Book of 3.4x: Is it justified?

On a P/B of 3.4x, Denali trades above the broader US Biotechs industry average of 2.4x, even though the stock sits at $19.62, well below analysts’ average target of $35.57.

P/B compares the company’s market value to its net assets on the balance sheet, which can matter for biopharma stocks where current earnings are negative and traditional P/E ratios are less useful. In this case, Denali is loss making, with a reported net loss of $508.02m and a return on equity that is described as negative, so the market is effectively pricing the research pipeline and future potential rather than current profitability.

At the same time, the company’s P/B of 3.4x is described as expensive against the US Biotechs industry average of 2.4x, yet as good value compared with a peer group average of 6.8x. That mix of signals suggests investors are paying a premium to the broader industry, but a discount to more closely matched peers that may have similar business models or development stages.

Given this spread, the P/B multiple sends a clear message. Versus the wider industry, Denali looks expensive on asset value. Versus closer peers, it looks cheaper, which may reflect differing views on the quality and risk of the pipeline rather than a simple bargain or overpayment.

Result: Price to book of 3.4x (ABOUT RIGHT)

However, the story still carries risks, including Denali’s reported net loss of $508.02m and the potential for setbacks across its early stage pipeline.

Next Steps

With both excitement around AVLAYAH and clear pipeline risks in play, this is a good time to look at the numbers yourself and decide how comfortable you are with the balance of uncertainty and potential. To weigh those trade offs and see the mix of concerns and positives flagged by our models, start with the 1 key reward and 2 important warning signs

Looking for more investment ideas?

If you only stop at Denali, you could miss other stocks that better fit your goals. Use screeners to widen your opportunity set with discipline.

• Target potential mispricings by scanning for companies that combine quality with attractive valuations through our 49 high quality undervalued stocks
• Strengthen your income stream by focusing on reliable cash returns using the 12 dividend fortresses
• Prioritise resilience by filtering for companies with lower overall risk profiles using the 71 resilient stocks with low risk scores

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.